Objective: The purposes of this study were to determine the role of surgical treatment and to identify factors affecting survival of patients undergoing resection of pulmonary metastatic tumors from esophageal carcinoma. Methods: We reviewed 33 patients who had undergone resection of pulmonary metastatic tumors from esophageal carcinoma after definitive treatment. Results: The operative morbidity rate was only 5%, no patients died within 30 days after resection, and complete resection was achieved in 30 patients. The overall 1-, 3-and 5-year survival rates after pulmonary metastasectomy were 79.4, 47.8 and 43.0%, respectively, and the median survival time was 17.9 months. The factors found on univariate analysis to affect survival significantly were disease-free interval <16 months and nodal involvement of the primary tumor. The most frequent pattern of initial recurrence after pulmonary resection was distant metastasis (70%). Conclusions: We demonstrated the safety and effectiveness of surgical resection for selected patients with pulmonary metastatic tumors from esophageal carcinoma. However, with a high recurrence rate in patients with negative prognostic factors, adjuvant systemic chemotherapy after pulmonary resection should be considered.
Introduction
Local and regional control of esophageal carcinoma has improved through the use of multimodal treatment combining surgical resection, radiation and chemotherapy. However, no effective or beneficial systemic treatment has been established for esophageal carcinoma that has metastasized to distant sites. The anticipated incidence of clinically detected distant metastases from esophageal carcinoma ranges from 14.1 to 66.7% (1) (2) (3) . One of the most common sites of metastasis is the lungs (2) (3) (4) . Nevertheless, surgical resection has become the standard treatment for selected pulmonary tumors metastatic from a variety of malignancies, including head and neck cancer, renal cell cancer, colorectal cancer, sarcoma and germ cell tumor (5-7). However, for patients with esophageal carcinoma, several studies have examined the role of pulmonary resection (8) (9) (10) , the clinical factors that best predict outcome remain unclear. The purposes of this study were to present our experiences with pulmonary resection of esophageal carcinoma and to clarify factors affecting poor survival.
Materials and methods

Patient population
From July 1992 to May 2013, 33 patients with pulmonary metastatic tumors who had been treated for esophageal carcinoma underwent surgical resection at the National Cancer Center Hospital East, Kashiwa, Japan. During the follow-up period after definitive treatment of primary esophageal tumor, newly detected round shaped pulmonary lesions on computed tomography (CT) were regarded as metastases from esophageal carcinoma. All patients who underwent pulmonary resection for metastatic tumors met the following criteria: (i) locally controlled primary tumor; (ii) metastatic disease limited to the lungs; (iii) preoperative assessment of complete resectability of all pulmonary lesions (even the lesions in bilateral lungs); and (iv) ability to tolerate the planned pulmonary resection. To confirm complete control of primary and extrapulmonary metastatic diseases, CT was re-examined in 1-2 months later after pulmonary metastasis diagnosis. Furthermore, upper gastrointestinal endoscopy and positron-emission tomography (PET) were also performed. Overall, 33 patients retrospectively analyzed with complete clinical and pathological data. Preoperative clinical staging for esophageal carcinoma was based on the Union for International Cancer Control-American Joint Committee on Cancer (UICC-AJCC) tumor, node, metastasis staging system, 7th edition.
All pathological specimens were examined by at least two pathologists with specific experience with esophageal and pulmonary tumors. Pulmonary lesions were diagnosed as metastatic esophageal tumors when they show histological findings, such as a similarity to the primary esophageal tumor, a tumor progression originating from the bronchial subepithelium and/or a discontinuity between the tumor and the bronchial epithelium. Lesions that originated within the bronchiolar epithelium were diagnosed as second primary lung tumors. Immunohistochemical examination was not added in this study.
Surgery
The aim of surgery for lung tumors was complete resection. The most common procedure was wedge resection, which was performed in 20 of the 33 patients. Segmental resection was performed in six patients, and lobectomy was performed in seven (Table 2) . Intra-operative rapid pathological diagnosis was routinely carried out and, if diagnosed as metastatic tumors, systemic lymph node dissection was not performed.
Follow-up
After discharge, all 33 patients were regularly followed up with routine physical and laboratory examinations at our hospital. Chest radiography and CT of the neck, chest and abdomen were performed annually to detect possible recurrent disease. The median follow-up period was 17.9 months (range: 2-92 months).
Statistical analysis
The disease-free interval (DFI) was calculated from the date of initiation of definitive treatment of primary esophageal carcinoma or, in patients with prior extrapulmonary recurrence, the date confirming complete control of extrapumonary metastatic diseases, until the date of pulmonary metastasis diagnosis. Survival time was defined as the interval from initial resection of pulmonary tumors to last follow-up or death. Length of survival was determined with the Kaplan-Meier method, and the log-rank test was used for univariate analysis. Cox's proportional hazards model was used for multivariate analysis, and the significance level used for adding and deleting a covariable from the model was a 0.05 and 0.10 level of probability, respectively.
A P < 0.05 was considered to indicate significance. All analyses were performed with SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA).
Results
Clinical characteristics of esophageal carcinoma
The characteristics of primary esophageal carcinoma are shown in Table 1 . Thirty patients were men and three were women. The median age was 67 years, and the age range was 46-78 years. As initial treatment for esophageal carcinoma, 16 CRT or ESD were clinically classified based on the endoscopic findings, contrast-enhanced CT and PET.
The histological type of the primary tumor was squamous cell carcinoma (SCC) in 32 patients and basaloid carcinoma in one. SCC was well-differentiated in seven cases, moderately differentiated in 20, and poorly differentiated in five.
Pulmonary clinical features and resection
Although preoperative diagnoses were pulmonary metastases and met to the criteria, we had two and one cases that were found to be primary lung cancers and a benign nodule respectively in the final pathological examinations. We inevitably excluded such cases in this study. Clinical features of metastatic lung tumor and results of pulmonary resection are shown in Table 2 . The median DFI was 15.5 months (range: 3-60 months). Of all, 11 patients had a history of extrapulmonary metastasis or recurrence, including six cases of locoregional recurrence, three of cervical lymph node metastasis, and one each of liver and pancreatic metastasis. Patients who had undergone salvage CRT or surgical interventions such as radiofrequency ablation for liver metastasis, pancreatic metastasectomy and lymphadenectomy achieved complete response at the time of pulmonary resection. All pulmonary resections were performed by video-assisted thoracoscopic surgery (VATS) (12 complete and 21 hybrid). A total of 27 (82%) patients had a solitary lung tumor, two patients had two tumors and four patients had three or more tumors. One patient with bilateral tumors underwent bilateral thoracotomy at the same time, and another patient with four tumors twice underwent wedge resection by unilateral thoracotomy. All pulmonary tumors in the 33 patients were pathologically diagnosed and confirmed to be metastases from esophageal carcinoma.
Complete resection of metastatic tumors in the lungs was achieved in 91% of the patients. Postoperative complications occurred in five patients (15%), pneumothorax in four and pneumonia in one. Median hospital stay after operation was 7.1 days (range: 4-33 days), and no patients died in the 30 days after surgery. Three patients with incomplete resection, which were microscopically diagnosed as positive margin (R1), received adjuvant chemotherapy with a combined regimen of cisplatin and 5-fluorouracil after metastasectomy.
Patterns of first failure
Overall, 23 (70%) patients had disease recurrence after pulmonary resection. The median time to recurrence was 5.0 months (range, 1.0-69.0). Recurrent disease developed in 13 patients (56.5%) within 6 months and 19 patients (82.6%) within 12 months. Distant metastasis, especially to the lungs, was the most common pattern of recurrence after resection (Table 3 ).
Survival and factors affecting overall survival
The overall 1-, 3-and 5-year survival rates of the 33 patients were 79.4, 47.8 and 43.0% respectively, and the median survival time after pulmonary metastasectomy was 17.9 months (range: 2-92 months). The overall survival curve is shown in Fig. 1 . Significant unfavorable prognostic factors identified with univariate analysis were DFI <16 months, nodal status of esophageal carcinoma (Table 4) , and overall survival curves according to both significant factors are shown in Fig. 2 . However, multivariate analyses of three factors, including DFI < 16 months, nodal status of esophageal carcinoma and incomplete resection, failed to identify these factors to be significant (DFI < 16-P = 0.062; hazard ratio (HR): 4.83; 95% confidence interval (CI) = 0.95-6.83, N-status-P = 0.074; HR: 2.61; 95% CI = 0.91-7.48 and incomplete resection-P = 0.48; HR: 1.65; 95% CI = 0.64-28.2).
Discussion
The most common site of distant metastasis in patients with esophageal carcinoma is the lungs (2-4). Furthermore, patients with esophageal carcinoma are at high risk for metachronous primary lung cancer (11) . Therefore, pulmonary malignancies are a major problem after definitive treatment of esophageal carcinoma. Distinguishing pulmonary metastasis from primary lung cancer in patients with esophageal SCC is difficult because of the similarities in histopathological and radiographic appearance. However, especially in head and neck SCC, the molecular genetic approach has helped clarify the fundamental distinction between pulmonary metastases and primary lung cancer (12, 13) . Treatment strategies for primary lung cancer differ from those for pulmonary metastases from esophageal carcinoma. For resectable second primary lung cancer, surgical intervention with curative intent should be considered (14, 15) , but for pulmonary metastases, systemic therapy or limited surgical resection should be considered. Distant metastasis is considered to be a systemic disease and is generally treated with chemotherapy. However, the results of chemotherapy for pulmonary metastases have been poor, with few complete responses and short survival (2) . In contrast, surgical resection has become the standard therapy for selected cases of a variety of malignancies metastasizing to the lungs, including head and neck cancer, renal cell cancer, colorectal cancer, sarcoma and germ cell tumor (5-7). However, there are few reports of surgical resection of pulmonary metastases from esophageal carcinoma (8) (9) (10) . Although previous reports have demonstrated the safety of surgical resection and its effect on survival, independent prognostic factors remain unclear.
The safety and curative ability of resection of malignant pulmonary tumors are well established (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . In the present study, no patients died within 30 days after resection, and complete resection was achieved in 91% of the patients. There are only three reports regarding long-term prognosis after resection of pulmonary metastases secondary to esophageal carcinoma, with 5-year survival rates of 29.6-43.5% (8-10) ( Table 5 ). The overall 5-year survival rate in our series (43.0%) was similar to previous studies. However, it is not easy to compare the survival rates, because of patient selection bias or additional treatments for recurrent disease after pulmonary metastasectomy. Moreover, as it is not easy to differentiate esophageal metastases from primary pulmonary SCCs, we could not fully exclude the possibility that some patients with primary lung cancer were included in the previous study population (8) .
Surgical treatment for pulmonary metastases from esophageal carcinoma in selected patients is a safe and may be a therapeutically beneficial procedure. There is little doubt that such favorable outcomes depend on good locoregional control of primary tumors and careful selection of candidates. Several factors affecting survival have been reported in previous studies. Shiono et al. (8) reviewed 49 patients from a database of The Metastatic Lung Tumor Study Group of Japan. They reported a 5-year survival rate of 29.6% and that the survival of patients with DFI < 12 months was significantly lower than in patients with DFI > 12 months. From a review of 23 patients, Ichikawa et al. (9) reported a 5-year survival rate of 43.5% and initial recurrence in the form of extrapulmonary metastasis as unfavorable prognostic factors. Furthermore, Kobayashi et al. (10) reported a 5-year survival rate of 34.1% and extrapulmonary metastases before pulmonary metastasectomy, poor differentiation of primary esophageal carcinoma, and DFI < 12 months as unfavorable prognostic factors. All authors described the necessity of further studies to verify the indications for pulmonary metastasectomy due to esophageal carcinoma (Table 5 ). In our study, univariate analysis identified DFI < 16 months and nodal involvement of primary tumor as significant factors affecting poor survival. Both factors reflect the malignant potential of esophageal cancer, and strongly affect patient prognosis: 13 of 33 patients with both risk factors survived a median 10.9 months (range: 4-68 months) after pulmonary metastasectomy. In contrast, six patients with neither factor survived a median 42.2 months (range: 5-86 months) (Fig. 2) .
The notion that multiple metastases affect survival is controversial because contradictory results have been obtained (8, 9) . At our institution, while no statistical difference was observed in survival between the number of metastases (P = 0.175), 3-year survival rate of patients with multiple pulmonary metastases is 0%, compared with 56.2% of patients with solitary pulmonary metastasis. Although the tumor number was not included in our criteria for pulmonary resection, such a case with apparent multiple metastases should be excluded.
It is uncertain whether our results may similarly apply to pulmonary metastasis from esophageal adenocarcinoma. There is no clear evidence supporting resection of pulmonary metastases from esophageal adenocarcinoma, because most primary tumor histology was SCC in our study. Nonetheless, our results suggest that a favorable outcome can be expected with meticulous patient selection and that surgical intervention has the potential to control pulmonary metastasis from esophageal carcinoma.
In the present study, disease recurred after pulmonary resection in 23 of 33 (70%) patients. Distant metastasis, especially to the lungs, was the most frequent pattern of recurrence after pulmonary resection. Although we could not reach a conclusion on the optimal criteria for pulmonary metastasectomy due to small number of cases with multiple metastases, the patients with "definitive" multiple metastases should be exclude from pulmonary resection. After pulmonary resection, closed follow-up is needed to detect pulmonary or extrapulonary relapses, not to avoid missing out on opportunity for radical treatment. Moreover, adjuvant chemotherapy also should be administered after pulmonary resection. To achieve further improvement of prognosis, a large-scale, multi-center, prospective study is needed to determine the selection criteria for pulmonary metastasectomy, and to evaluate accurate prognostic factors.
Conclusions
With meticulous patient selection, we have confirmed that pulmonary resection after treatment of esophageal carcinoma is safe and increases the likelihood of long-term survival. We found that DFI < 16 months and nodal involvement of primary tumor were negatively correlated with survival. The pattern of initial recurrence after pulmonary resection was most often distant metastasis. Therefore, adjuvant systemic chemotherapy after pulmonary resection should be considered. AC: adenocarcinoma; BC: basaloid carcinoma; CS: carcinosarcoma; DFI; disease-free interval; Ex: esophagectomy; NA: not available; OS: overall survival; RFS: relapse-free survival; RT, radiotherapy.
